ORY — ORYZON Genomics SA Income Statement
0.000.00%
Last trade - 00:00
- €124.35m
- €125.78m
- 22
- 31
- 45
- 21
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | — | -0.683 | -3.2 | -2.38 | -1.14 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.84 | 4.29 | 7.01 | 5.49 | 4.55 |
Operating Profit | -3.84 | -4.29 | -7.01 | -5.49 | -4.55 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.58 | -4.78 | -7.18 | -6.56 | -6.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | -3.68 | -3.4 | -4.69 | -4.23 | -3.35 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.68 | -3.4 | -4.69 | -4.23 | -3.35 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.68 | -3.4 | -4.69 | -4.23 | -3.35 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.081 | -0.064 | -0.089 | -0.077 | -0.055 |
Dividends per Share |